LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 1209 | 2761 | 4012 | 0.6898 | 0.6137 |
MCF7 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 3874 | 4203 | 0.9233 | 0.9139 |
MCF7 | BX-912 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 3738 | 4203 | 0.8904 | 0.8752 |
MCF7 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 3388 | 4203 | 0.8081 | 0.7768 |
SK-BR-3 | PIK-93 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4442 | 4245 | 1.0468 | 1.0584 |
MCF7 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 681 | 4012 | 0.1703 | -0.2823 |
MCF7 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4004 | 4203 | 0.9540 | 0.9491 |
SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP5 | 72 | hr | 1401 | 1595 | 4245 | 0.3753 | 0.0810 |
MCF7 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 1209 | 3122 | 4012 | 0.7787 | 0.7308 |
SK-BR-3 | AT-7519 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 2511 | 4168 | 0.6031 | 0.4499 |
SK-BR-3 | Radicicol | 0.04 | uM | LJP6 | 72 | hr | 1401 | 2168 | 4168 | 0.5199 | 0.3189 |
SK-BR-3 | AZD7762 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1907 | 4168 | 0.4574 | 0.2158 |
SK-BR-3 | Withaferin A | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4473 | 4168 | 1.0732 | 1.0919 |
SK-BR-3 | Alvocidib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1580 | 4168 | 0.3793 | 0.0795 |
MCF7 | MK2206 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 2425 | 4012 | 0.6048 | 0.4946 |
SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3852 | 4168 | 0.9237 | 0.9010 |
MCF7 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1209 | 3665 | 4012 | 0.9147 | 0.9003 |
MCF7 | HG-5-88-01 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 3074 | 4012 | 0.7659 | 0.7136 |
SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4863 | 4245 | 1.1519 | 1.1903 |
MCF7 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 2794 | 4203 | 0.6647 | 0.5926 |
MCF7 | AZD-6482 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4152 | 4203 | 0.9873 | 0.9851 |
MCF7 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4412 | 4203 | 1.0522 | 1.0586 |
MCF7 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1209 | 4112 | 4012 | 1.0253 | 1.0295 |
MDA-MB-231 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1235 | 3304 | 4660 | 0.7086 | 0.6698 |
MDA-MB-231 | NVP-TAE684 | 0.04 | uM | LJP6 | 72 | hr | 1235 | 3892 | 4405 | 0.8837 | 0.8696 |